Liranaftate

Liranaftate

[Suppression of experimental inflammation by anti-fungal agent liranaftate in mice].[Pubmed:20185866]

Nihon Ishinkin Gakkai Zasshi. 2010;51(1):7-11.

To evaluate the anti-inflammatory activity of the thiocarbamate antifungal agent Liranaftate, the edema and the neutrophil accumulation detected by the activity of neutrophil marker enzyme, myeloperoxidase (MPO), were examined following application of Liranaftate to mouse ears with inflammation induced by phorbol 12-myristate 13-acetate (PMA). Topical 20 microl administration of Liranaftate in a dose-range between 1-4% suppressed the increase in ear thickness 6 hr after PMA application dose-dependently. Similarly, it decreased the weight increase of an ear section after 24 hr dose-dependently. More than 1% of Liranaftate also suppressed augmentation of MPO activity of the ear section. This and histological observation indicate that Liranaftate treatment suppressed neutrophil accumulation in PMA-applied ear lesion. From these results, we discussed that Liranaftate might suppress inflammatory symptoms caused by trychophytosis in a clinical condition.

[Anti-fungal drug liranaftate suppresses fungal element-promoted production of IL-8 in normal human keratinocytes].[Pubmed:19001760]

Nihon Ishinkin Gakkai Zasshi. 2008;49(4):319-22.

Dermatophytes reside in the stratum corneum of the epidermis, and one scenario in superficial dermatophytosis is that fungi stimulate keratinocytes to secrete chemokines, thereby attracting inflammatory cells. We investigated the effect of the cytokine / chemokine production of keratinocytes solely stimulated by fungal elements. The fungal elements beta-D-glucan and trichophytin from Trichophyton rubrum and Trichophyton mentagrophytes augmented production of IL-8 and IL-1 alpha of cultured normal human epidermal keratinocytes. It was found that keratinocytes can recognize elements of dermatophytes as a pathogen. Next we examined the effect of Liranaftate, a representative Japanese thiocarbamate antifungal agent, on the production of IL-8 and IL-1 alpha. Keratinocytes were incubated with this antifungal drug in the presence of beta -glucan or trichophytin. Augmented production of IL-8 was profoundly suppressed by the addition of Liranaftate to the culture in a dose-dependent manner. Clinically, Liranaftate an antifungal drug with IL-8-decreasing activity may reduce infiltration of neutrophils in the skin and their invasion into the epidermis.

[Suppression of experimental footpad inflammatory reaction by anti-fungal agent liranaftate in mice].[Pubmed:22728596]

Med Mycol J. 2012;53(2):129-33.

To evaluate the effect of the thiocarbamate antifungal agent Liranaftate on inflammation and itchiness, footpad edema by phorbol 12-myristate 13-acetate (PMA) and the paw-licking accompanying by perceptual stimuli by compound 48/80 were examined. The effect of Liranaftate application to mouse footpad on paw-licking time by compound 48/80 was observed. Topical administration of 4% Liranaftate 1 hr before compound 48/80 did not suppress the paw-licking time, while pyrilamine, an anti-histamine agent, suppressed it significantly. As Liranaftate was reported to suppress the ear inflammation induced by PMA, the effect of this agent on the footpad edema by PMA was examined. Liranaftate application significantly suppressed the increase in footpad swelling 24 hr after application of PMA, as true with ear inflammation. In this condition, we measured the paw-licking time by compound 48/80, but the suppression of time was not observed by the agent with or without the suppression of footpad inflammation. From these observations, we conclude that Liranaftate treatment suppresses late phase inflammatory reaction in feet, perhaps accompanied by cytokine production, though it may not relieve acute stimuli and itchiness through an anti-histamine effect directly.

[Fungicidal activity of liranaftate against dermatophytes].[Pubmed:19194054]

Nihon Ishinkin Gakkai Zasshi. 2009;50(1):9-13.

The fungicidal activities of the thiocarbamate antifungal agent Liranaftate were compared to those of luliconazole, amorolfine hydrochloride and ketoconazole against twelve stock strains of three species of dermatophytes. The MICs of 0.001-0.009 microg/ml of luliconazole against Trichophyton rubrum (n=6)were the lowest among the agents tested, but its MCCs were considerably higher. Consequently, the antifungal potency of luliconazole was considered fungistatic. In contrast to this, the MCCs of 0.009-0.039 microg/ml of Liranaftate against T. rubrum were the lowest and similar to its MICs. These results showed that Liranaftate was fungicidal. All antifungals except ketoconazole tended to be fungicidal against both T. mentagrophytes (n=3)and Microsporum gypseum (n=3). In time-kill studies, Liranaftate showed the greatest decrease to a below detection limit in viable counts of T. rubrum. The degree of killing of the strain by amorolfine was not greater than that seen by Liranaftate, and little reduction of the viable counts by luliconazole and ketoconazole was observed irrespective of concentrations of the agents. Conversely, there were no differences among four agents in fungicidal activities against T.mentagrophytes. The killing activities of Liranaftate against M. gypseum were also higher than those of comparable agents, as true of T. rubrum described above. In this study we found that it was harder to kill T. rubrum than other dermatophytes. Therefore, Liranaftate with its potent fungicidal activities was suggested an efficacious agent for the treatment of dermatophytes.